KAT2B and Huntington disease: Thus, our results indicate that, regarding the disease-modifying effect of Gcn5, the H3.3K14Q modification is epistatic over Gcn5 and suggest that the involvement of GCN5 in HD pathology can be primarily attributed to the reduced acetylation of the H3K14 residue.